ES2312168T3 - Compuestos para la supresion de la transactivacion de hiv por tat. - Google Patents

Compuestos para la supresion de la transactivacion de hiv por tat. Download PDF

Info

Publication number
ES2312168T3
ES2312168T3 ES95933830T ES95933830T ES2312168T3 ES 2312168 T3 ES2312168 T3 ES 2312168T3 ES 95933830 T ES95933830 T ES 95933830T ES 95933830 T ES95933830 T ES 95933830T ES 2312168 T3 ES2312168 T3 ES 2312168T3
Authority
ES
Spain
Prior art keywords
baselineskip
compound
tat
ndga
seap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933830T
Other languages
English (en)
Spanish (es)
Inventor
Ru Chih Huang
John N. Gnabbe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2312168T3 publication Critical patent/ES2312168T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
ES95933830T 1994-09-30 1995-09-22 Compuestos para la supresion de la transactivacion de hiv por tat. Expired - Lifetime ES2312168T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US316341 1994-09-30
US08/316,341 US6365787B1 (en) 1994-09-30 1994-09-30 Compounds for the suppression of HIV TAT transactivation

Publications (1)

Publication Number Publication Date
ES2312168T3 true ES2312168T3 (es) 2009-02-16

Family

ID=23228649

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933830T Expired - Lifetime ES2312168T3 (es) 1994-09-30 1995-09-22 Compuestos para la supresion de la transactivacion de hiv por tat.

Country Status (10)

Country Link
US (4) US6365787B1 (2)
EP (1) EP0783474B1 (2)
JP (2) JP3966900B2 (2)
CN (2) CN100413835C (2)
AT (1) ATE403635T1 (2)
AU (1) AU700481B2 (2)
CA (1) CA2200991C (2)
DE (1) DE69535804D1 (2)
ES (1) ES2312168T3 (2)
WO (1) WO1996010549A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20030219407A1 (en) * 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US7728036B2 (en) 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
AU2004249124A1 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
EP1845787B1 (en) * 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
KR20090006062A (ko) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
NZ581837A (en) * 2007-05-11 2012-08-31 Convatec Technologies Inc Stoma seal coupling including stoma seal support
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US20130331414A1 (en) * 2011-01-10 2013-12-12 Susana Valente Inhibitors of Retroviral Replication
US9877978B2 (en) 2012-02-03 2018-01-30 The Johns Hopkins University Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer
WO2014015136A2 (en) * 2012-07-18 2014-01-23 The Johns Hopkins University Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
US5008294A (en) 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5195965A (en) * 1991-03-07 1993-03-23 Shantha Totada R Method and apparatus for localized treatment of human viral infections and cancers
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
DE69739105D1 (de) 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Also Published As

Publication number Publication date
EP0783474A1 (en) 1997-07-16
US5663209A (en) 1997-09-02
WO1996010549A1 (en) 1996-04-11
US6291524B1 (en) 2001-09-18
CN1762951A (zh) 2006-04-26
EP0783474A4 (2) 1997-08-27
DE69535804D1 (de) 2008-09-18
EP0783474B1 (en) 2008-08-06
CN1211335C (zh) 2005-07-20
AU3633995A (en) 1996-04-26
CN100413835C (zh) 2008-08-27
JP2006273869A (ja) 2006-10-12
JP3966900B2 (ja) 2007-08-29
ATE403635T1 (de) 2008-08-15
CA2200991C (en) 2007-07-10
CN1162301A (zh) 1997-10-15
USRE40246E1 (en) 2008-04-15
JPH10509421A (ja) 1998-09-14
US6365787B1 (en) 2002-04-02
AU700481B2 (en) 1999-01-07
CA2200991A1 (en) 1996-04-11

Similar Documents

Publication Publication Date Title
JP3966900B2 (ja) Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物
Gnabre et al. Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography
ES2873449T3 (es) Composición rica en hidroxitirosol a partir de agua de vegetación de aceitunas y método de uso del mismo
ES2308810T3 (es) Uso de un compuesto ingenano para la elaboracion de un medicamento para el tratamiento del cancer.
ES2295482T3 (es) Extracto de plantas chinas.
WO1996010549A9 (en) Compounds for the suppression of hiv tat transactivation
ES2227318T3 (es) Extracto estable y mejorado de hypericum perforatum l., un procedimiento para su preparacion y su utilizacion como medicamento topico.
US20100098676A1 (en) Synergistic anti-inflammatory and antioxidant dietary supplement compositions
JPH0378365B2 (2)
RU2246299C2 (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
Palomino et al. Screening of South American plants against human immunodeficiency virus: preliminary fractionation of aqueous extract from Baccharis trinervis
Choubisa et al. Reversibility of natural dental fluorosis
RU2155052C1 (ru) Комплексный антипаразитарный препарат, не обладающий иммуносупрессией
ES2205219T3 (es) Extracto purificado de harpagophytum procumbens y/o harpagophytum zeyheri dence, procedimiento para su preparacion y su uso.
Ameen et al. Chromatography-Spectroscopic Isolated Mo11 (Moringa oleifera) and Ms06 (Musa sapientum) Positively Immunomodulated ACE2 Levels in Blood, Kidney and Liver of Rats
Neal et al. Cactus alkaloids X: Isolation of hordenine and N‐methyltyramine from Ariocarpus kotschoubeyanus
CN116283874A (zh) 一种头花杜鹃杂萜类化合物、提取方法及应用
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
Pratap et al. Total phenolic and flavonoid content, antioxidant effects and antidiarrheal activity of balacaturbhadrika churna-an Ayurvedic preparation
Selvamani et al. Diuretic activity of isolated fractions from petroleum ether extract of Commiphora berryi
KR19990077000A (ko) 아산화물 단위로 제조된 대환식 화합물
US6641851B2 (en) Herbal laxative preparation
ES2761429T3 (es) Composición farmacéutica antiviral, que contiene un extracto de Juncus acutus
Farmer et al. A study on the medicinal potential of Artemisia afra, a traditionally used herb in Namibia
Han et al. Pharmacokinetics of a chemoprotective agent, 2-(allylthio) pyrazine, after intravenous and oral administration to rats: Hepatic and gastric first-pass effects